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Abstract
Background: Steroid use has prolonged ambulation in Duchenne muscular dystrophy (DMD) and combined with
advances in respiratory care overall management has improved such that cardiac manifestations have become the
major cause of death. Unfortunately, there is no consensus for DMD-associated cardiac disease management. Our
purpose was to assess effects of steroid use alone or in combination with angiotensin converting enzyme
inhibitors (ACEI) or angiotension receptor blocker (ARB) on cardiovascular magnetic resonance (CMR) derived
circumferential strain (εcc).
Methods: We used CMR to assess effects of corticosteroids alone (Group A) or in combination with ACEI or ARB
(Group B) on heart rate (HR), left ventricular ejection fraction (LVEF), mass (LVM), end diastolic volume (LVEDV) and
circumferential strain (εcc) in a cohort of 171 DMD patients >5 years of age. Treatment decisions were made
independently by physicians at both our institution and referral centers and not based on CMR results.
Results: Patients in Group A (114 studies) were younger than those in Group B (92 studies)(10 ± 2.4 vs. 12.4 ± 3.2
years, p < 0.0001), but HR, LVEF, LVEDV and LVM were not different. Although εcc magnitude was lower in Group B
than Group A (-13.8 ± 1.9 vs. -12.8 ± 2.0, p = 0.0004), age correction using covariance analysis eliminated this
effect. In a subset of patients who underwent serial CMR exams with an inter-study time of ~15 months, εcc
worsened regardless of treatment group.
Conclusions: These results support the need for prospective clinical trials to identify more effective treatment
regimens for DMD associated cardiac disease.
Background
Duchenne muscular dystrophy (DMD) is an X-linked
recessive disorder affecting approximately 1:3,500 males
[1-3]. Boys with DMD are currently treated with corticos-
teroids at a young age to prolong ambulation. This ther-
apy combined with improvements in respiratory care
have resulted in increased survival [4-6] such that DMD-
associated heart disease is now the leading cause of mor-
tality [7-11]. Myocardial changes, as a result of the lack
of dystrophin, consist of cell membrane degradation,
interstitial inflammation, edema, fatty replacement and
fibrosis [12-15]. Despite reports in small cohorts of the
beneficial cardiovascular effects of corticosteroids [6,16]
and angiotensin converting enzyme inhibitors (ACEI)/
angiotensin receptor blockers (ARB) [17-19], there is no
consensus regarding the management of DMD-associated
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any medium, provided the original work is properly cited.cardiac disease. In the absence of conclusive randomized
clinical trial data, steroids, ACEI, ARB, beta blockers (BB)
and/or digoxin have been used empirically [20,21]; bene-
ficial effects of positive inotropic agents have been
reported in boys with depressed left ventricular function
and advanced cardiac disease [22].
Defining clinical endpoints for cardiac therapy in DMD
boys is challenging. Recent studies from our center and
others have shown that indices of global left ventricular
(LV) function, e.g. mass, volume and ejection fraction (EF)
are not adequate to detect cardiac dysfunction in young
DMD patients [23-25], but myocardial strain (ε), an indi-
cator of local myocardial deformation normalized to its
original dimension, can detect occult cardiac disease early
i nt h ec o u r s eo fD M Dd e s p i t en o r m a lE F .F u r t h e r ,
depressed εcc magnitude correlates with disease progres-
sion [24,25].
The purpose of this study was to retrospectively com-
pare cardiac effects of corticosteroid monotherapy versus
corticosteroids plus ACEI or ARB in a cohort of DMD
patients followed at our center. We compared effects on
both global LV function (EF) and local LV function (εcc)
determined by cardiovascular magnetic resonance (CMR).
Methods
DMD patients >5 years of age who underwent CMR from
February 2006 to February 2010 were identified from the
CMR database at Cincinnati Children’s Hospital Medical
Center (CCHMC). The diagnosis of DMD was confirmed
by physical examination and identification of a dystro-
phin mutation. This study was approved by the Institu-
tional Review Board.
Patients were identified for inclusion in one of two treat-
ment groups. Group A was only treated with corticoster-
oids (either deflazacort or prednisone). Group B was being
treated with corticosteroids plus ACEI (lisinopril or enala-
pril) or ARB (losartan). All patients in Group B had been
treated with ACEI/ARB for a minimum of 12 months
prior to CMR, and all patients in both groups had been
treated with corticosteroids for at least 12 months prior to
CMR. Initiation of corticosteroids and ACEI/ARB was
determined exclusively by treating physician preference
and were not based on CMR results. DMD boys not trea-
ted with corticosteroids or treated with beta blockers were
excluded.
CMR studies were conducted on either a 3 Tesla (Trio,
Siemens Medical Solutions, Erlangen, Germany) or 1.5
Tesla (Signa Excite, General Electric Healthcare, Milwau-
kee, WI) scanner based on clinical availability, indepen-
dent of the patient’s clinical status or prior type or field
strength of the first study. Cardiac functional imaging
was performed using retrospective ECG-gating, segmen-
ted Steady State Free Precession (SSFP) technique after
localized shimming and/or frequency adjusting. Subjects
were breath-held as tolerated; for those subjects who
could not adequately breath-hold, a free breathing tech-
nique with multiple signal averaging was used. Standard
imaging included a short axis stack of cine SSFP images
from cardiac base to apex; the short axis was prescribed
as the perpendicular plane to the left ventricular long
axis in 2 and 4 chamber views as previously described
[26,27]. Typical scan parameters included FOV = 32-38
cm, slice thickness = 5-6 mm, gap = 1-2 mm, NEX = 2
(breath hold; 4-5 for free breathing), TE/TR = 1.4/2.8
(Siemens), TE/TR = 2.0/4.0 (GE), in-plane resolution =
1.2- 2.2 mm. A minimum of 12 slices were performed,
with 20 phases/slice. The typical temporal resolution of
the cine SSFP images was 30-40 ms; they and were
adjusted according to the patient heart rate and ability to
breath-hold. The RF flip angles were set between 50°-70°
dependent on the patient weight, height and the SAR
level.
Tagged cine CMR images were acquired in the short
axis of the midventricle at the level of the papillary mus-
cles using an ECG-triggered segmented k-space fast gra-
dient echo sequence with spatial modulation of
magnetization in orthogonal planes. Tag imaging was
performed prior to administration of Gadolinium. Grid
tag spacing was 7-8 mm. The scan parameters used were:
field of view = (30-32) × (25-26) cm
2, slice thickness =
6 mm, flip = 20°, TE/TR = 3 ms/6.6 ms (GE), = 3 ms/4.2
ms (Siemens), views per segment = 8 (GE), = 7-9 (Sie-
mens). Tagged images were analyzed using the HARmo-
nic Phase (HARP, Diagnosoft, CA, USA) technique
[23,28-32]. Only the mid-ventricular slice was analyzed,
based on our experience and others’ [23] of limited
reproducibility of the basal and apical slices. Details of
the εcc analysis have been previously described by Hor et
al. [24]. The εcc data was exported to a spreadsheet file
for analysis.
Cardiac functional imaging was performed to deter-
mine LV volumes, mass and EF using semi-automated
endocardial and epicardial segmentation (QMASS
v.6.1.5, Medis Medical Imaging Systems) Netherlands
and circumferential strain (εcc) using HARmonic Phase
analysis (HARP, Diagnosoft, Palo Alto, California) as
previously described [23-25,29-31,33-35].
R e s u l t sa r ee x p r e s s e da sm e a n±S Df o rc o n t i n u o u s
data and as percentages and numbers for categorical
data. Continuous variables were compared using two-
sample t-test and categorical variables were compared
using Fisher exact-test. Analysis of covariance
(ANCOVA) was used to assess the effect of medications
on several clinical measurements with age as a continu-
ous covariate in the model. All tests were 2-sided, and a
p-value < 0.05 was considered statistically significant.
SAS version 9.2 (SAS Institute Inc., Cary, NC) was used
for all analyses.
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We identified 171 DMD patients > 5 years of age that
had undergone CMR examination. A total of 256 studies
were available for review as a number of patients had
multiple studies. We excluded 50 studies for either no
corticosteroid treatment at the time of study (36 studies)
or treatment with beta-blockers at the time of study (14
studies). The remaining 206 studies from 136 patients
were divided into two groups: Group A (corticosteroids
alone, n = 114) and Group B (corticosteroids plus ACEI
or ARB, n = 92). Group A patients were significantly (p <
0.0001) younger (10 ± 2.4 years) than Group B patients
(12.4 ± 3.2 years).
The average steroid dose was similar between Group A
and Group B (0.7 ± 0.29 mg/kg/day, range 0.1-1.9 vs. 0.6 ±
0.22 mg/kg/day, range 0.1 - 1.3, p = 0.48). The patients in
Group B were on standard dose of ACEI (0.16 ± 0.29 mg/
kg/day, range 0.04 - 1.23) and ARB (0.73 ± 0.29 mg/kg/
day, range 0.34 - 1.23) (Table 1).
Heart rate, LV EF, LV end diastolic volume (LVEDV)
and LV mass (LVM) were not different between the two
groups. LVEF averaged across all patients in this cohort
was normal, but εcc magnitude was significantly lower in
Group B (-12.8 ± 2) versus Group A patients (-13.8 ± 1.9,
p = 0.0004). To determine the extent to which differences
in the two groups was an effect of patient age, we per-
formed a covariance analysis and treated age as a continu-
ous variable (Table 2). The covariance model confirmed
the lack of significant differences between Groups A and B
with respect to heart rate, EF, LVEDV, LVM, LVRI or εcc
after controlling for age, implying lack of difference
between the two groups other than the use of cardiac
medications in Group B.
Additionally, to assess serial changes in EF and εcc we
identified patients in Group A (n = 28) and B (n = 31)
who underwent 2 CMR studies during the observation
period. This included 11 patients who crossed from
Group A to B between sequential studies. Among indivi-
duals with 2 studies, EF and εcc values were compared
between the two studies (Figure 1). EF changes between
the first and second study were variable across three
groups, while the majority of patients had decline in εcc
magnitude over the same study period. In Group A,
50% (14/28) patients had decrease EF while the other
50% (14/28) had increase EF. Of Group A patients, 7%
(2/28) had changes in EF by > 10%, however one
increased by almost 15% and the other decrease by 12%.
Both patient s continue to have normal EF (>55%) on
both studies. One patient had EF < 55% on the first
study which remained the same on the second study
and another patient had EF that decline from 59% to
54%. However, only 14% (4/28) of Group A subjects had
an increase εcc magnitude while 86% (24/28) had wor-
sening of εcc magnitude. The findings for Group B were
similar, with 68% (21/31) of patients having decrease EF
and 32% (10/31) of patients with increase EF over the
two study. Of Group B patients, 28% (9/32) had changes
in EF by > 10% with 6 patients having decrease EF and
3 patients with increase EF on the follow-up study. Of
these, One patient started with an EF of 53% and
increased to 64% on the follow-up study. Of the 6
patients with decrease in EF, three had EF < 55% while
the other three continue to have normal EF on the fol-
low-up study. As in Group A, 84% (26/31) of the Group
B patients had decrease εcc, while only 16% (5/31) sub-
jects showed improvement in εcc magnitude. For the
patients that crossed from Group A to B, the percent of
patients with improved EF was 45% (5/11) while 55%
(6/11) had decline in EF. The percent of patients with
an increase in εcc magnitude was 18% (2/11) but 82%
(9/11) had worsening of εcc magnitude (Figure 1). The
average time between studies was the same across
Group A, Group B and patients who transitioned from
Group A to B. LVEF did not change significantly
between baseline and follow-up in all three groups
(Table 3). While εcc worsened from initial to follow-up
CMR exam in all three groups, reduction in εcc only
reached statistical significance in Group B (Table 3).
Table 1 DMD Patients characteristics
Parameter Steroid Only (A)(n = 114 ) Steroid plus ACEI_ARB (B)(n = 92 ) P-value
Age (yrs) 10.0 ± 2.4 12.4 ± 3.2 <0.0001
Heart Rate (bpm) 101 ± 19 104 ± 15 0.2498
LVEDV (mL) 82.5 ± 21.8 86.7 ± 24.8 0.2023
LVM (g) 58.6 ± 19.4 62.1 ± 19.8 0.1031
EF (%) 64.2 ± 6.1 62.8 ± 7.5 0.1414
εcc (%) -13.8 ± 1.9 -12.8 ± 2.0 0.0004
Steroid dose (gram/kg/day) 0.7 ± 0.29 0.6 ± 0.22 0.4838
ACE-I dose (gram/kg/day) N/A 0.16 ± 0.08 N/A
ARB dose (gram/kg/day) N/A 0.73 ± 0.29 N/A
Abbreviations: ACE-I = Angiontension Converting Enzyme Inhibitor, ARB = Angiotension Receptor Blocker, bpm = beat per minute, Clinic Prior to CMR = Previous
Clinic Visit Documenting Medication and Dose Prior to Cardiac Magnetic Resonance Imaging Study, DMD = Duchenne Muscular Dystrophy, εcc = Circumferential
Strain, EF = Ejection Fraction, LVEDV = Left Ventricular Endiastolic Volume, LVM = Left Ventricular Mass.
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This study represents the largest cohort of DMD
patients analyzed for the effect of medical therapy on
the natural history of DMD-associated cardiac disease.
Albeit retrospective, these results suggest that treatment
with either an ACEI or ARB does not arrest the decline
in DMD-associated cardiac function in patients receiv-
ing corticosteroids. In fact, we found a statistically sig-
nificant worsening in εcc in patients taking both
corticosteroids and ACEI or ARB, suggesting that cur-
rent approaches are inadequate in arresting decline in
cardiac function.
Clinical assessment of DMD-associated cardiac disease
is particularly challenging, as overt decompensation typi-
cally occurs only in the terminal stages of disease at a time
when clinical assessment of cardiac function is limited. A
sensitive and specific parameter such as εcc could thus
assume great importance in management of these patients.
Previous studies have shown that changes in εcc precede
decline in LVEF in DMD-associated cardiac disease as
well as in both hypertrophic and hypertensive cardiomyo-
pathy [24,36-38]. Using such an early marker of subclinical
disease in a cohort with preserved LVEF, we were unable
to detect an improvement with standard therapies.
Assessment of cardiac effects of corticosteroid therapy in
animal models and patients has historically yielded mixed
results. For example, corticosteroids have been shown to
improve systolic function in children with myocarditis but
Figure 1 Serial ejection fraction (EF) and circumferential strain (εcc). Red, indicates decreased EF and εcc magnitude; blue, indicates increase
EF and εcc magnitude and black, indicates mean EF and εcc values. Panels A-C show EF of each subject plotted serially; there was no significant
change in mean EF across all three groups. Individually 14/28 (50%) in Group A, 21/31(68%) in Group B and 5/11 (45%) in Group A to B
transition had decrease EF, while 14/28 (50%), 10/31 (32%) and 6/11 (55%) of the individuals in the respective groups had increase EF. Panels D-F
show εcc of each subject plotted serially; although all three groups had lower absolute εcc on the follow-up study, only Group B subjects had a
significant decline (p = 0.007). Individually εcc magnitude decreased more consistently across all three groups, with 24/28 (86%) in Group A, 26/
31 (84%) in Group B and 9/11 (82%) in Group A to B. Unlike EF, only a small fraction of the individuals have improvement of εcc magnitude on
follow-up study with 4/28 (14%), 5/31 (31%) and 2/11 (18%) of the individuals in the respective group having an increase εcc value on follow-up
study.
Table 2 Analysis of covariance summary results:
Comparisons between steroid only vs. steroid plus
ACEI_ARB (medication) adjusted for age as a continuous
variable
Response Variable Medication Age
F-statistics P-value F-statistics P-value
Heart Rate (bpm) 1.11 0.2930 0.00 0.9979
LVEDV (mL) 1.33 0.2503 37.01 <0.0001
LVM (g) 2.19 0.1405 64.38 <0.0001
EF (%) 0.03 0.8594 9.10 0.0029
εcc (%) 1.74 0.1885 30.85 <0.0001
Abbreviations: ACE-I = Angiontension Converting Enzyme Inhibitor, ARB =
Angiotension Receptor Blocker, bpm = beat per minute,?εcc = Circumferential
Strain, EF = Ejection Fraction, LVEDV = Left Ventricular Endiastolic Volume,
LVM = Left Ventricular Mass.
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Page 4 of 8Table 3 Results from Serial CMR Exams Across DMD Treatment Groups
Group/Patients Time Interval (months) Group A (Steroids); n = 28
Mean = 14.9 ± 5.6
Range = 8.5-29.7
Group B (Steroids plus ACEI/ARB); n = 31
Mean = 15.1 ± 5.9 Range = 8.4-35.8
Group A to B; n = 11
Mean = 15.6 ± 5.9 Range = 5.8-25.5
CMR Study Study 1 Study 2 P-value Study 1 Study 2 P-value Study 1 Study 2 P-value
Age (yrs) 9.30 ± 1.5 10.5 ± 1.6 <0.005 11.7 ± 3.4 12.97 ± 3.4 0.148 10.8 ± 2.5 12.0 ± 2.2 0.252
HR (bpm) 101 ± 21 99 ± 16 0.762 105 ± 14 105 ± 15 0.996 100 ± 14 102 ± 18 0.682
LVEDV (mL) 82.7 ± 19.3 86.5 ± 21.6 0.494 84.9 ± 29.2 90.0 ± 30.8 0.499 85.6 ± 18.6 81.2 ± 15.6 0.556
LVM (g) 57.1 ± 15.1 57.7 ± 16.9 0.890 60.9 ± 21.4 65.0 ± 21.4 0.478 61.3 ± 31.2 60.1 ± 14.0 0.909
EF (%) 64.6 ± 6.3 64.4 ± 5.8 0.906 64.9 ± 6.7 62.2 ± 9.1 0.194 61.2 ± 5.0 63.8 ± 5.8 0.261
εcc (%) -14.3 ± 1.6 -13.7 ± 1.5 0.135 -13.4 ± 1.7 -12.1 ± 1.6 0.007 -13.2 ± 1.8 -11.9 ± 2.7 0.179
Abbreviations: BMP = beat per minute, DMD = Duchenne Muscular Dystrophy, εcc = Circumferential Strain, EF = Ejection Fraction, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker,
HR = heart rate, LVEDV = Left Ventricular Endiastolic Volume (milliliter), LVM = Left Ventricular Mass (gram).
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8not with dilated cardiomyopathy [39]. Markham et al
demonstrated that freedom from ventricular dysfunction
at approximately 50 months between retrospectively-
reviewed echocardiograms was 93% for steroid treated ver-
sus 53% for untreated DMD cases [6]. However, in a
mouse model of dystrophin deficiency, Bauer et al demon-
strated acceleration of cardiac dysfunction in steroid trea-
ted animals [40]. Recently, Pereira et al [41] observed
normalization of multidirectional (radial, longitudinal and
circumferential) strain assessed by 2D echo speckle track-
ing in Cushing syndrome patients following normalization
of corticosteroid excess; they concluded that corticosteroid
excess not only induced LV hypertrophy and diastolic dys-
function but also subclinical systolic dysfunction, which
reverses upon normalization of corticosteroid excess.
While there is universal agreement that steroids prolong
ambulation in the DMD patient population (reviewed in
[21]), the current study failed to identify a cardioprotective
effect of steroids.
Several studies have suggested beneficial effects of
ACEI on LV function in small cohorts [17-19,42]. In a
murine DMD model, Bauer et al showed hemodynamic
benefit to dystrophin-deficient mice treated with ACEI
alone [40]. Jefferies et al suggested that this effect may be
linked to specific mutations [19] in humans, but Rama-
ciotti et al [42] did not confirm this finding. In addition
to εcc, we found no difference in EF between baseline and
15 months, which is at odds with the findings of Duboc
et al [17] who found that treatment with perindopril
delayed the onset and progression of LV dysfunction in
children. There are several possible explanations for the
differences in findings. First, in our cohort, the time
between the serial CMR studies might be insufficient to
develop detectable LV EF decline. However, one would
expect to detect more subclinical changes using the more
s e n s i t i v em e a s u r eL Vεcc. Furthermore, without an
untreated control group, the fact that εcc magnitude
declined only slightly may represent a “good” outcome,
as LV function of untreated patients may decline more
precipitously. Despite smaller studies reporting benefit of
ACEI and BB, there is no published data demonstrating
longer life expectancy in DMD boys undergoing “adult-
like” CHF therapy.
A long-standing hypothesis regarding DMD-associated
cardiac disease pathogenesis is that loss of membrane
integrity is a primary event leading to myocyte degenera-
tion. Intermittent tears in the cell membrane permit influx
of calcium that then functions as a primary inducer of a
destructive cascade culminating in myocyte necrosis and
replacement fibrosis [43]. Although there has been intense
interest in treating DMD-associated cardiac disease, suc-
cessful therapies remain elusive [22,44-46]. Findings in the
current study underscore the need for randomized studies
in DMD population. As in cases of heart failure in adult
population, development of heart failure with normal EF
starts early (HFNEF) and proceeds to systolic dysfunction.
Of interest, studies in adult HFNEF patients treated with
ACEI or BB have not demonstrated improvement in mor-
tality compared to placebo [47-49]. In boys with DMD,
dystrophin mutation dictates eventual LV dysfunction and
once systolic dysfunction and myocardial fibrosis develop,
clinical disease typically progresses very rapidly and long-
term survival (as seen in adult patients with LV systolic
dysfunction) is poor. As such, the window of opportunity
to treat DMD-associated cardiac disease needs to be
advanced to when εcc is abnormal but EF has not yet
begun its inexorable declined.
Study Limitations
Study design based on physician preference is a major
limitation of the study and includes retrospective, mostly
cross-sectional data with no control group and with
strong confounding of group allocation by age of boys
being prescribed therapy. Older boys tended to be on
combination treatment while younger boys were often
treated with steroids alone. Further, longitudinal data is
limited. Other confounding factors are very difficult to
control for but are beyond the scope of this manuscript.
As such, no firm conclusions can be drawn regarding the
response rates to steroid or ACEI/ARB use. Further, find-
ings are limited to patients >5 years since in our experi-
ence patients < 5 years of age cannot undergo CMR
without sedation. While it is possible, that 15 months fol-
low-up was too short to detect therapeutic benefits, stu-
dies in other populations with preserved EF but
measurable diastolic dysfunction have shown improve-
ment in circumferential and longitudinal strain 12
months after ARB initiation [50].
Conclusions
These results support the need for rigorous, prospective
clinical trials to identify more effective treatment regi-
mens for DMD-associated cardiac disease.
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